Semaglutide may be the better option if: Cost is the primary concern compounded semaglutide offers the most affordable path to GLP-1 therapy in 2026 You have cardiovascular disease the SELECT trial demonstrated significant reduction in major cardiovascular events with semaglutide, giving it the strongest CV evidence base of any GLP-1 medication
Check Your Eligibility Free Consultation (Prospective Patients) Starting July 1, 2026 , Medicare Part D covers Wegovy, Zepbound, and Foundayo for weight loss through the new GLP-1 Bridge program
Boost Metabolism & Enhance Fat Breakdown: , combined with apple cider vinegar and the powerful Moringa extract , helps the body utilize fat stores more effectively for energy
Stress management : Chronic stress promotes cortisol elevation, which can impair weight loss
The NICE guidance (TA875) for semaglutide emphasises that pharmacological treatment should be accompanied by a reduced-calorie diet and increased physical activity